Lyophilization monophase solution technique for improvement of the physicochemical properties of an anticancer drug, flutamide.
Flutamide (FLT), an anticancer drug for prostatic carcinoma, has poor aqueous solubility and low oral bioavailability. This study describes the ability of beta-cyclodextrin (betaCD) and hydroxypropyl-beta-cyclodextrin (HPbetaCD) to form complexes with flutamide with enhanced solubility and dissolution rate in vitro. FLT-CD lyophilized dispersions (LDs) were prepared via lyophilization monophase solution technique using tertiary butyl alcohol (TBA) as a cosolvent. FLT showed an A(L)-type phase solubility diagram consistent with a linear increase in drug solubility as a function of CD concentration. Gas chromatography indicated that the LDs contain 0.02-0.03% w/w residual TBA. Based on the data from differential scanning calorimetry (DSC) and X-ray diffractometry (XRD), FLT was fully amorphous in 1:5 FLT-HPbetaCD LD as indicated by complete disappearance of FLT endothermic and diffraction peaks. The Fourier transform infrared (FTIR) spectra indicated that a FLT-CD interaction took place in the lyophilized complex. The particle sizes of 1:1 FLT-betaCD and FLT-HPbetaCD LDs were 0.92 and 0.82microm, with a high surface area (484.55 and 705.68m(2)/g) and porosity (769.46 and 1020.99e(-3)ml/g), respectively. The dissolution rate of FLT from its CD complexes was enhanced significantly. After 30min in 0.1N HCl, about 73% and 86% of FLT were dissolved from 1:5 FLT-betaCD and FLT-HPbetaCD LDs, respectively, compared to only 13.45% of pure drug. No endothermic peak corresponding to FLT melting was detected in 1:5 FLT-HPbetaCD LD after storage at 20 degrees C and 45% relative humidity for 90days thus indicating the stability of this binary system. These data suggest that cyclodextrins might be useful adjuncts in preparation of immediate-release formulations of FLT.
Elgindy
Nazik
N
Department of Industrial Pharmacy, University of Alexandria, Alexandria, Egypt.
Elkhodairy
Kadria
K
Molokhia
Abdallah
A
Elzoghby
Ahmed
A
D000073738:2-Hydroxypropyl-beta-cyclodextrin; D000970:Antineoplastic Agents / Q000737:chemistry*; D003460:Crystallization; D004339:Drug Compounding / Q000379:methods*; D004355:Drug Stability; D005485:Flutamide / Q000737:chemistry*; D005612:Freeze Drying / Q000379:methods*; D010316:Particle Size; D019999:Pharmaceutical Solutions / Q000737:chemistry; D012995:Solubility; D013499:Surface Properties; D047392:beta-Cyclodextrins / Q000737:chemistry
D000970:Antineoplastic Agents; D019999:Pharmaceutical Solutions; D047392:beta-Cyclodextrins; D000073738:2-Hydroxypropyl-beta-cyclodextrin; D005485:Flutamide